Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paladin’s Impavido Could Set A Price Tag For Priority Review Vouchers

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval of the leishmaniasis treatment by its December user fee date would give the Canadian sponsor a voucher for a priority review, which it is likely to sell to another company.


Related Content

For Sale: Knight Therapeutics Seeks Buyers For Impavido Priority Review Voucher
BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval
Impavido Gets Big Thumbs Up, Weighed Down By Dosing Concern
Paladin’s Impavido Poised For Smooth Advisory Committee
NCATS May Consider Requesting “Active” Compounds For Repurposing Program
FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
Ilaris Safety Data Inadequate For Gout Indication, FDA Panel Says
How Much Is A Priority Review Voucher Worth? Perhaps $387 Mil.
FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts